<?xml version="1.0" encoding="iso-8859-1"?>
<!-- generator="FeedCreator 1.7.2" -->
<rss version="2.0">
    <channel>
        <title>MedWorm Tags: antibody</title>
        <description>MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'antibody'.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=%22antibody%22&t=%22antibody%22&r=Exact&o=d&f=tag]]></link>
        <lastBuildDate>Sat, 03 Sep 2011 02:12:03 +0100</lastBuildDate>
        <item>
            <title>2011 ASCO: Additional Phase III Study Data Support the Potential Role of Avastin in Newly-Diagnosed &amp; Recurrent Ovarian Cancer</title>
            <link>http://www.medworm.com/index.php?rid=4921689&amp;cid=t_159330_136_f&amp;fid=37846&amp;url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F06%2F09%2F2011-asco-additional-phase-iii-study-data-support-the-potential-role-of-avastin-in-newly-diagnosed-recurrent-ovarian-cancer%2F</link>
            <description>Positive results from two bevacizumab (Avastin®) phase III clinical studies were presented at the 2011 American Society of Clinical Oncology Annual Meeting on June 4. The data reported add to the growing body of evidence in support of bevacizumab use to treat recurrent and newly-diagnosed ovarian cancer. Positive results from two bevacizumab (Avastin®) phase III [...] (Source: Libby's H*O*P*E*)</description>
            <author>Libby's H*O*P*E*</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4921689</comments>
            <pubDate>Thu, 09 Jun 2011 23:15:13 +0100</pubDate>
            <guid isPermaLink="false">4921689</guid>        </item>
        <item>
            <title>Futures in Biotech 71: Genomics, Proteomics, Cellular Immunity, and Anti-Matter</title>
            <link>http://www.medworm.com/index.php?rid=4636113&amp;cid=t_159330_139_f&amp;fid=38879&amp;url=http%3A%2F%2Fwww.virology.ws%2Ffib0071.flv</link>
            <description>I joined Marc Pelletier, Andre Nantel, and George Farr on episode 71 of Futures in Biotech for a conversation about the 1000 genome project, the billion dollar human proteome, how antibodies block viral infection, and capturing anti-matter.
Download audio FiB #71 (42 MB .mp3, 87 minutes)
				
				
Download video (211 MB .mp4) (Source: virology blog)</description>
            <author>virology blog</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4636113</comments>
            <pubDate>Tue, 30 Nov 2010 20:39:39 +0100</pubDate>
            <guid isPermaLink="false">4636113</guid>        </item>
        <item>
            <title>Antibodies neutralize viral infectivity inside cells</title>
            <link>http://www.medworm.com/index.php?rid=4158813&amp;cid=t_159330_139_f&amp;fid=38879&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FVirologyBlog%2F%7E3%2FTmOWer8-iJc%2F</link>
            <description>Antibodies are an important component of the host defense against viral infection. These molecules, produced 7-14 days after infection, neutralize viral infectivity, thereby limiting the spread of infection. Antibodies are thought to neutralize viral infectivity in several ways: by forming noninfectious aggregates that cannot enter cells, or by blocking virion attachment to cells or uncoating (figure). A new mechanism has just joined this list, in which antibody bound virions are degraded in the cell cytoplasm.
A cytoplasmic protein called TRIM21 (tripartite motif-containing 21) was recently found to bind with high affinity to the conserved regions of antibody molecules. The presence of this activity in many mammalian species suggested that there could be ways that antibodies operate withi...</description>
            <author>virology blog</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4158813</comments>
            <pubDate>Thu, 11 Nov 2010 18:34:51 +0100</pubDate>
            <guid isPermaLink="false">4158813</guid>        </item>
        <item>
            <title>Detecting viral proteins in infected cells or tissues by immunostaining</title>
            <link>http://www.medworm.com/index.php?rid=4017874&amp;cid=t_159330_139_f&amp;fid=38879&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FVirologyBlog%2F%7E3%2FXOYZJusvX68%2F</link>
            <description>Many virological techniques are based on the specificity of the antibody-antigen reaction. Examples in our virology toolbox include western blot analysis and ELISA. While very useful, these methods cannot be used to visualize viral proteins in infected cells or tissues. To do that we must turn to immunostaining.
In direct immunostaining (illustrated), an antibody that recognizes a viral antigen is coupled directly to an indicator (a fluorescent dye or an enzyme). Indirect immunostaining is a more sensitive method because a second antibody is coupled to the indicator. The second antibody recognizes a common epitope on the virus-specific antibody. Multiple second antibodies can bind to the first antibody, leading to an increased signal from the indicator compared to direct immunostaining.
To...</description>
            <author>virology blog</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4017874</comments>
            <pubDate>Thu, 30 Sep 2010 15:06:04 +0100</pubDate>
            <guid isPermaLink="false">4017874</guid>        </item>
        <item>
            <title>Primary Biliary Cirrhosis</title>
            <link>http://www.medworm.com/index.php?rid=3938294&amp;cid=t_159330_83_f&amp;fid=34856&amp;url=http%3A%2F%2Finsidesurgery.com%2F2010%2F09%2Fprimary-biliary-cirrhosis%2F</link>
            <description>Pathophysiology
1) progressive inflammation and destruction of the intrahepatic bile ducts 2) causes development of cirrhosis 3) likely has an autoimmune component
Signs and Symptoms
1) fatigue 2) jaundice 3) pruritus 4) hepatomegaly 5) splenomegaly 6) xanthelasma 7) diagnosis is often made on asymptomatic laboratory detection
Characteristic Test Findings
Laboratory &amp;#8211; 1) increased alkaline phosphatase (3 times normal value) 2) mildly elevated AST and ALT 3) antimitochondrial antibody
Histology/Gross Pathology
Ludwig&amp;#8217;s classification describes histology &amp;#8211; portal and periportal scarring and fibrosis and cirrhosis
Associated Conditions
1) osteoporosis 2) hypercholesterolemia 3) thyroid disease (15%) 4) scleroderma (15%) 5) joint pain 6) dry eyes/mouth (75%) 7) gallstones (30...</description>
            <author>Inside Surgery</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3938294</comments>
            <pubDate>Mon, 06 Sep 2010 20:20:23 +0100</pubDate>
            <guid isPermaLink="false">3938294</guid>        </item>
        <item>
            <title>Detection of antigens or antibodies by ELISA</title>
            <link>http://www.medworm.com/index.php?rid=3946234&amp;cid=t_159330_139_f&amp;fid=38879&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FVirologyBlog%2F%7E3%2Fh1f6DEG1Yr8%2F</link>
            <description>A more rapid method than Western blot analysis to detect a specific protein in a cell, tissue, organ, or body fluid is enzyme-linked immunosorbent assay, or ELISA. This method, which does not require fractionation of the sample by gel electrophoresisis, is based on the property of proteins to readily bind to a plastic surface.
To detect viral proteins in serum or clinical samples, a capture antibody, directed against the protein, is linked to a solid support such as a plastic 96 well microtiter plate, or a bead. The clinical specimen is added, and if viral antigens are present, they will be captured by the bound antibody. The bound viral antigen is then detected by using a second antibody linked to an enzyme. A chromogenic molecule &amp;#8211; one that is converted by the enzyme to an easily ...</description>
            <author>virology blog</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3946234</comments>
            <pubDate>Fri, 16 Jul 2010 16:28:49 +0100</pubDate>
            <guid isPermaLink="false">3946234</guid>        </item>
        <item>
            <title>Mononucleosis</title>
            <link>http://www.medworm.com/index.php?rid=3617782&amp;cid=t_159330_83_f&amp;fid=34856&amp;url=http%3A%2F%2Finsidesurgery.com%2F2010%2F05%2Fmononucleosis%2F</link>
            <description>Pathophysiology
infection with Epstein-Barr virus (or sometimes CMV with slightly different clinical presentation) in adolescence or early adulthood
Signs and Symptoms
1) prodrome of fatigue, malaise, and myalgias 2) tender but mobile lymphadenopathy (especially in posterior cervical chain) 3) fever 4) exudate pharyngitis 5) splenomegaly 6) splenic rupture (0.5%) 7) mouth petechiae 8) gingivitis 9) abdominal pain 10) rash (10%) 11) symptoms usually resolve in 3-4 weeks
Characteristic Test Findings
Laboratory &amp;#8211; 1) leukocytosis with at least 10% lymphocytes 2) presence of Paul-Bunnell heterophile antibody (this is the basis of the diagnostic monospot test) 3) presence of transient cold agglutinins 4) increased AST, ALT, alkaline phosphatase
Histology/Gross Pathology
1) atypical lymphcy...</description>
            <author>Inside Surgery</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3617782</comments>
            <pubDate>Mon, 31 May 2010 18:58:03 +0100</pubDate>
            <guid isPermaLink="false">3617782</guid>        </item>
        <item>
            <title>Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer</title>
            <link>http://www.medworm.com/index.php?rid=3311889&amp;cid=t_159330_136_f&amp;fid=37846&amp;url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F02%2F25%2Fgenentech-announces-positive-results-of-avastin-phase-iii-study-in-women-with-advanced-ovarian-cancer%2F</link>
            <description>Genentech announces positive results of Avastin Phase III study (GOG 218) in women with advanced ovarian cancer. The study showed that women who continued maintenance use of Avastin alone, after receiving Avastin in combination with chemotherapy, lived longer without the disease worsening compared to those who received chemotherapy alone. This is the first Phase [...] (Source: Libby's H*O*P*E*)</description>
            <author>Libby's H*O*P*E*</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3311889</comments>
            <pubDate>Thu, 25 Feb 2010 18:40:30 +0100</pubDate>
            <guid isPermaLink="false">3311889</guid>        </item>
        <item>
            <title>Systemic Lupus Erythematous (SLE)</title>
            <link>http://www.medworm.com/index.php?rid=3306783&amp;cid=t_159330_83_f&amp;fid=34856&amp;url=http%3A%2F%2Finsidesurgery.com%2F2010%2F02%2Fsystemic-lupus-erythematous-sle%2F</link>
            <description>Pathophysiology
1) systemic disorder with tissue damage secondary to autoantibodies and immune complex deposition 2) cause is unknown but likely requires an environmental stimulus (example is ultraviolet light) in presence of many susceptibility genes
Signs and Symptoms 
1) butterfly rash on face 2) short hairs in frontal scalp (&amp;#8221;lupus hairs&amp;#8221;) 3) &amp;#8220;carpet tack&amp;#8221; skin lesions 4) pericarditis 5) pericardial effusions 6) pleurisy 7) pleural effusions  focal or diffuse proliferative nephritis 9) abdominal pain 10) blindness 11) fatigue (often debilitating) 12) cognitive dysfunction (&amp;#8221;lupus cerebritis&amp;#8221;) 13) subcutaneous nodules 14) puffiness of hands and feet 15) swan-neck deformities of fingers
Characteristic Test Findings
Laboratory &amp;#8211; 1) anti-ANA antibo...</description>
            <author>Inside Surgery</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3306783</comments>
            <pubDate>Thu, 25 Feb 2010 01:54:46 +0100</pubDate>
            <guid isPermaLink="false">3306783</guid>        </item>
        <item>
            <title>Reinfection with 2009 influenza H1N1</title>
            <link>http://www.medworm.com/index.php?rid=3126477&amp;cid=t_159330_139_f&amp;fid=38879&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FVirologyBlog%2F%7E3%2F9F6kjjjpdzY%2F</link>
            <description>In healthy individuals, the first encounter with a virus leads to a primary antibody response. When an infection occurs with the same or a similar virus, a rapid antibody response occurs that is called the secondary antibody response. Antibodies are critical for preventing many viral infections, including influenza. But reinfection may occur if we encounter the same virus before the primary response is complete.
Recently three cases of confirmed infection with 2009 influenza H1N1 were reported in Chile. The first patient had laboratory confirmed infection; treatment with oseltamivir resolved symptoms after 48 hours. Twenty days later the patient developed a second bout of laboratory confirmed influenza which was treated with amantadine. The second patient acquired laboratory confirmed i...</description>
            <author>virology blog</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3126477</comments>
            <pubDate>Mon, 28 Dec 2009 21:09:44 +0100</pubDate>
            <guid isPermaLink="false">3126477</guid>        </item>
        <item>
            <title>Natural antibody protects against viral infection</title>
            <link>http://www.medworm.com/index.php?rid=3016941&amp;cid=t_159330_139_f&amp;fid=38879&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FVirologyBlog%2F%7E3%2FAAd62pyT5Ec%2F</link>
            <description>Antibodies produced by infection with a virus, or after immunization with viral vaccines, are effective at preventing viral disease. However humans and higher primates contains &amp;#8220;natural antibodies&amp;#8221; which are present in serum before viral infection. Natural antibodies can activate the classical complement pathway leading to lysis of enveloped virus particles long before the adaptive immune response is activated.
Many natural antibodies are directed against the disaccharide galactose α(1,3)-galactose (α-Gal) (illustration), which is found as a terminal sugar on glycosylated cell surface proteins. Humans, apes, and Old World monkeys lack the gene encoding the enzyme galactosyltransferase, which attaches α-Gal to membrane proteins. Lower primates, most other animals, and bact...</description>
            <author>virology blog</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016941</comments>
            <pubDate>Tue, 06 Oct 2009 17:37:01 +0100</pubDate>
            <guid isPermaLink="false">3016941</guid>        </item>
        <item>
            <title>Trojan Horse* For Ovarian Cancer–Nanoparticles Turn Immune System Soldiers Against Tumor Cells</title>
            <link>http://www.medworm.com/index.php?rid=2662628&amp;cid=t_159330_136_f&amp;fid=37846&amp;url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F08%2F01%2Ftrojan-horse-for-ovarian-cancer-nanoparticles-turn-immune-system-soldiers-against-tumor-cells%2F</link>
            <description>In a feat of trickery, Dartmouth Medical School immunologists have devised a Trojan horse to help overcome ovarian cancer, unleashing a surprise killer in the surroundings of a hard-to-treat tumor. Using nanoparticles&amp;#8211;ultra small bits&amp;#8211; the team has reprogrammed a protective cell that ovarian cancers have corrupted to feed their growth, turning the cells back [...] (Source: Libby's H*O*P*E*)</description>
            <author>Libby's H*O*P*E*</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2662628</comments>
            <pubDate>Sat, 01 Aug 2009 21:59:42 +0100</pubDate>
            <guid isPermaLink="false">2662628</guid>        </item>
        <item>
            <title>Adaptive immune defenses: Antibodies</title>
            <link>http://www.medworm.com/index.php?rid=2741088&amp;cid=t_159330_139_f&amp;fid=38879&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FVirologyBlog%2F%7E3%2FXhG1BwK-CIs%2F</link>
            <description>With the looming prospect of mass immunization against influenza, it&amp;#8217;s important to understand how vaccines work. To do this we must have a good understanding of adaptive immune defenses. Today we&amp;#8217;ll begin a discussion of the humoral arm of the adaptive immune response &amp;#8211; antibodies.
Antibodies are large proteins produced by vertebrates that play important roles in identifying and eliminating foreign objects. The basic structural unit is composed of two heavy chains and two light chains, as shown in this diagram.

Antibodies bind other molecules known as antigens. Binding occurs in a small region near the ends of the heavy and light chain called the hypervariable region (labeled only on one arm in the figure). As the name implies, this region is extremely variable, which ...</description>
            <author>virology blog</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2741088</comments>
            <pubDate>Wed, 22 Jul 2009 20:16:04 +0100</pubDate>
            <guid isPermaLink="false">2741088</guid>        </item>
        <item>
            <title>Diabetes Research News</title>
            <link>http://www.medworm.com/index.php?rid=2616738&amp;cid=t_159330_111_f&amp;fid=36048&amp;url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FAHeartyLife%2F%7E3%2FmFTON_zX3KA%2F</link>
            <description>Here&amp;#8217;s some exciting news for diabetics. In fact, the more I read about diabetes treatment these days, the more excited I become. A group of researchers took non-obese diabetic mice which had recently developed Type 1 diabetes, and injected them with an &amp;#8220;anti-CD3 monoclonal antibody for five days, followed by transplantation of embryonic pancreatic tissue, and, for short-term glucose control, implantation of a subcutaneous insulin pellet.&amp;#8221;

Most of the mice maintained normal blood sugars after the removal of the insulin pellet. The transplanted cells were shown to migrate to the pancreas of the test subjects.
Is this a cure for diabetes? Sorry - but no. Still, this is exciting research that tells more and more about how the body tolerates transplanted cells and tissue. Th...</description>
            <author>A Hearty Life</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2616738</comments>
            <pubDate>Sun, 19 Jul 2009 20:55:40 +0100</pubDate>
            <guid isPermaLink="false">2616738</guid>        </item>
        <item>
            <title>Mesothelin – A Potential New Target For Ovarian Cancer ImmunoTherapy</title>
            <link>http://www.medworm.com/index.php?rid=2417147&amp;cid=t_159330_136_f&amp;fid=37846&amp;url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F05%2F18%2Fmesothelin-a-potential-new-target-for-ovarian-cancer-immunotherapy%2F</link>
            <description>Researchers have generated altered immune cells that are able to shrink, and in some cases eradicate, large tumors in mice. The immune cells target mesothelin, a protein that is highly expressed, or translated in large amounts from the mesothelin gene, on the surface of several types of cancer cells. The approach, developed by researchers at [...] (Source: Libby's H*O*P*E*)</description>
            <author>Libby's H*O*P*E*</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2417147</comments>
            <pubDate>Tue, 19 May 2009 04:51:22 +0100</pubDate>
            <guid isPermaLink="false">2417147</guid>        </item>
        <item>
            <title>Preclinical Results Validate Lpathomab As A Potential Future Treatment for Ovarian Cancer</title>
            <link>http://www.medworm.com/index.php?rid=2365380&amp;cid=t_159330_136_f&amp;fid=37846&amp;url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F04%2F23%2Fpreclinical-results-validate-lpathomab-as-a-potential-future-treatment-for-ovarian-cancer%2F</link>
            <description>&amp;#8220;Lpath, Inc. &amp;#8230; , the category leader in bioactive-lipid-targeted therapeutics, reported compelling new in vivo and in vitro results relating to its preclinical drug candidate, Lpathomab, in various ovarian cancer studies &amp;#8230;&amp;#8221;

&amp;#8220;Lpath Presents Compelling New Preclinical Results of Its Anti-Cancer Drug Candidate, Lpathomab(TM), at the AACR 100th Annual Meeting -

New In Vivo and In Vitro [...] (Source: Libby's H*O*P*E*)</description>
            <author>Libby's H*O*P*E*</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2365380</comments>
            <pubDate>Thu, 23 Apr 2009 23:28:32 +0100</pubDate>
            <guid isPermaLink="false">2365380</guid>        </item>
        <item>
            <title>Stanford Researchers Harness Nanoparticles To Track Cancer Cell Changes</title>
            <link>http://www.medworm.com/index.php?rid=2349515&amp;cid=t_159330_136_f&amp;fid=37846&amp;url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F04%2F15%2Fstanford-researchers-harness-nanoparticles-to-track-cancer-cell-changes%2F</link>
            <description>&amp;#8220;A new imaging technology could give scientists the ability to simultaneously measure as many as 100 or more distinct features in or on a single cell. In a disease such as cancer, that capability would provide a much better picture of what&amp;#8217;s going on in individual tumor cells. A Stanford University School of Medicine team [...] (Source: Libby's H*O*P*E*)</description>
            <author>Libby's H*O*P*E*</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2349515</comments>
            <pubDate>Wed, 15 Apr 2009 21:38:07 +0100</pubDate>
            <guid isPermaLink="false">2349515</guid>        </item>
        <item>
            <title>CNTO 328 Shows Promise For Ovarian Cancer In Small Clinical Trial, Say U.K. Scientists.</title>
            <link>http://www.medworm.com/index.php?rid=2326616&amp;cid=t_159330_136_f&amp;fid=37846&amp;url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F04%2F07%2Fcnto-328-shows-promise-for-ovarian-cancer-in-small-clinical-trial-say-uk-scientists%2F</link>
            <description>British scientists have developed and clinically tested a drug that could prolong the lives of ovarian cancer patients. A clinical trial of the drug, codenamed CNTO328, has been carried out at the Centre for Experimental Cancer Medicine, which is part of Barts and the London School of Medicine and Dentistry. &amp;#8230; The drug is an [...] (Source: Libby's H*O*P*E*)</description>
            <author>Libby's H*O*P*E*</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2326616</comments>
            <pubDate>Sun, 12 Apr 2009 03:04:22 +0100</pubDate>
            <guid isPermaLink="false">2326616</guid>        </item>
        <item>
            <title>HUPO PSI-PAR: standard format for protein affinity reagents</title>
            <link>http://www.medworm.com/index.php?rid=2323808&amp;cid=t_159330_132_f&amp;fid=35016&amp;url=http%3A%2F%2Fpeanutbutter.wordpress.com%2F2009%2F04%2F07%2Fhupo-psi-par-standard-format-for-protein-affinity-reagents%2F</link>
            <description>Image via Wikipedia



HUPO PSI-PAR: standard format for protein affinity reagents is now available for Public Comment on the PSI Web site for the next 30 days. The public comment period enables the wider community to provide feedback on a proposed standard before it is formally accepted, and thus is an important step in the standardisation process. This message is to encourage you to contribute to the standards development activity by commenting on the material that is available online. We invite both positive and negative comments. If negative comments are being made, these could be on the relevance, clarity, correctness, appropriateness, etc, of the proposal as a whole or of specific parts of the proposal. If you do not feel well placed to comment on this document, but know someone who ...</description>
            <author>peanutbutter</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2323808</comments>
            <pubDate>Tue, 07 Apr 2009 08:34:35 +0100</pubDate>
            <guid isPermaLink="false">2323808</guid>        </item>
        <item>
            <title>All change in 2009, no more academia</title>
            <link>http://www.medworm.com/index.php?rid=2115491&amp;cid=t_159330_132_f&amp;fid=35016&amp;url=http%3A%2F%2Fpeanutbutter.wordpress.com%2F2009%2F01%2F19%2Fall-change-in-2009-no-more-academia%2F</link>
            <description>Image via Wikipedia



Last week I completed what was my first week of working in academia in 2009 and also my last for the foreseeable future. I have decided to leave academia, as well as Newcastle to take a position in a Biotech company in Cambridge.
I have certainly enjoyed just over 5 years working in Newcastle encompassing my PhD and a postdoc. Within that time my research interests have developed from representing scientific data, to data standards to ontology development. I am still maintaining some of my research interests in my new position. I will be working for an antibody company called Abcam, and as part of my role I will be investigating how to represent their product catalogue as an ontology and how users can have a more direct interaction with it.
I am really looking forwar...</description>
            <author>peanutbutter</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2115491</comments>
            <pubDate>Mon, 19 Jan 2009 22:04:26 +0100</pubDate>
            <guid isPermaLink="false">2115491</guid>        </item>
        <item>
            <title>New hope for multiple sclerosis sufferers</title>
            <link>http://www.medworm.com/index.php?rid=2382468&amp;cid=t_159330_107_f&amp;fid=38577&amp;url=http%3A%2F%2Fbiosingularity.wordpress.com%2F2008%2F10%2F24%2Fnew-hope-for-multiple-sclerosis-sufferers%2F</link>
            <description>A drug which was developed in Cambridge and initially designed to treat a form of leukaemia has also proven effective against combating the debilitating neurological disease multiple sclerosis (MS).
The study, led by researchers from the University of Cambridge, has found that alemtuzumab not only stops MS from advancing in patients with early stage active relapsing-remitting [...] (Source: Biosingularity)</description>
            <author>Biosingularity</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2382468</comments>
            <pubDate>Fri, 24 Oct 2008 00:01:22 +0100</pubDate>
            <guid isPermaLink="false">2382468</guid>        </item>
        <item>
            <title>ImClone’s Erbitux: Approved in Japan For Colorectal Cancer Use</title>
            <link>http://www.medworm.com/index.php?rid=1637996&amp;cid=t_159330_136_f&amp;fid=36051&amp;url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FCancerCommentary%2F%7E3%2F339122109%2F</link>
            <description>ImClone Systems, Inc.&amp;#8217;s advanced colorectal cancer drug has now received regulatory approval in Japan.
ERBITUX(R) (cetuximab) has received marketing authorization in Japan for use in treating patients with advanced or metastatic colorectal cancer (mCRC).
Specifically, this approval allows for the use of ERBITUX to treat patients with epidermal growth factor receptor (EGFR)-positive, curatively unresectable (inoperable), advanced or recurrent CRC, and allows the use of ERBITUX plus irinotecan in second and further lines of mCRC.
With this approval, ERBITUX is the first ever EGFR-targeted monoclonal antibody to be submitted for and receive marketing authorization in Japan.
ERBITUX (cetuximab) is a monoclonal antibody (IgG1 Mab) designed to inhibit the function of a molecular structure ...</description>
            <author>Cancer Commentary</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1637996</comments>
            <pubDate>Fri, 18 Jul 2008 16:00:28 +0100</pubDate>
            <guid isPermaLink="false">1637996</guid>        </item>
        <item>
            <title>Individuals infected with certain parasite 24% more likely to develop schizophrenia</title>
            <link>http://www.medworm.com/index.php?rid=1198675&amp;cid=t_159330_109_f&amp;fid=34750&amp;url=http%3A%2F%2Fpsychcentral.com%2Fblog%2Farchives%2F2008%2F02%2F03%2Findividuals-infected-with-certain-parasite-24-more-likely-to-develop-schizophrenia%2F</link>
            <description>It has long been hypothesized that it’s unhealthy for pregnant women to change the cat litter, but now more then ever, pregnant women have a reason to hand over the pooper-scooper responsibilities. A recent study published in The American Journal of Psychiatry claims that individuals exposed to the Toxoplasma gondii parasite, which is carried by cats and farm animals, have a 24% greater risk of developing schizophrenia. The researchers that completed this study are planning further studies on whether treating the toxoplasma gondii infection can stop the progression of the schizophrenia. 
	This parasite can be found on undercooked meat and cat feces. It is thought that the parasite can live for up to a year in a damp shaded environment. If you are pregnant or you have children already, yo...</description>
            <author>World of Psychology</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1198675</comments>
            <pubDate>Mon, 04 Feb 2008 00:03:41 +0100</pubDate>
            <guid isPermaLink="false">1198675</guid>        </item>
        <item>
            <title>Elimination Of B Cells Aids In The Treatment Of Diabetes</title>
            <link>http://www.medworm.com/index.php?rid=1068767&amp;cid=t_159330_134_f&amp;fid=36049&amp;url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FDiabetesNotes%2F%7E3%2F194876647%2F</link>
            <description>Yale school of Medicine, New Haven has developed the means to establish the depletion of B cells in diabetes and proven to reverse the disease that was established in mice.
Pretty darn cool. Up to now scientists have been able to do this with RA, rheumatoid arthritis, but haven&amp;#8217;t had the tools to recreate this same type of research among diabetic cells.
In the study, autoimmune diabetes&amp;#8211;susceptible mice were engineered such that their B cells expressed human CD20. Depletion of B cells in these mice before they showed signs of diabetes, using a single dose of a CD20-specific antibody, delayed and/or reduced the onset of disease.
It is truly amazing how we can dissect how our bodies work and recreate different situations to enhance and further science!
Share This (Source: Diabete...</description>
            <author>Diabetes Notes</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1068767</comments>
            <pubDate>Tue, 04 Dec 2007 10:45:06 +0100</pubDate>
            <guid isPermaLink="false">1068767</guid>        </item>
        <item>
            <title>Pharmalot… Pharmalittle… Break Time</title>
            <link>http://www.medworm.com/index.php?rid=988523&amp;cid=t_159330_150_f&amp;fid=35777&amp;url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F176772939%2F</link>
            <description>As the day wears on, it may be a good idea to break for a cup of, well, something or take a quick stroll to keep the circulation going. Here are a few items, meanwhile, to help you clear your head&amp;#8230;
Wyeth Recalls Cough &amp;#038; Cold Meds With Faulty Cups (Yahoo/Reuters)
Cambridge Antibody To Change Name To MedImmune (Yahoo/AP)
China Raises Standards For Drug Licensing (Yahoo/AP)
Shire Launches Website For Clinical Trial Results (PharmaTimes)
Share / E-mail (Source: Pharmalot)</description>
            <author>Pharmalot</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=988523</comments>
            <pubDate>Mon, 29 Oct 2007 17:45:58 +0100</pubDate>
            <guid isPermaLink="false">988523</guid>        </item>
    </channel>
</rss>

